Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Smart Microgel Could Repair and Replace Damaged Organs

By HospiMedica International staff writers
Posted on 23 Jun 2025

Repairing or replacing damaged organs remains a central challenge in regenerative medicine, where delivering therapeutic cells or creating viable tissue structures often requires delicate, controlled environments. More...

Conventional microgel production methods frequently rely on harsh chemicals or multi-step recovery processes that can damage living cells or introduce contaminants. Researchers have now developed a new microfluidics tool that generates 'smart' microgel droplets capable of supporting sensitive biomedical applications without compromising safety or functionality.

The new microfluidics tool named UQ-Surf was developed by researchers from the University of Queensland (Brisbane, QLD, Australia) and focuses on regenerative medicine. UQ-Surf is designed to produce high volumes of uniform, biocompatible microgel droplets at remarkable speed and precision. The UQ-Surf tool can generate thousands of microdroplets per minute, each acting as a temperature-responsive environment ideal for cell therapies and tissue engineering. Unlike conventional systems, the microgels produced with UQ-Surf do not require harmful chemical demulsifiers or post-processing treatments to isolate the encapsulated materials. This eliminates the risk of contamination and preserves the biological integrity of the contents. The platform's core innovation lies in its ability to encapsulate living materials without exposing them to toxic agents, making the droplets safe for clinical and translational applications.

The UQ-Surf platform has already been patented and implemented in laboratory settings, demonstrating its readiness for broader use. Its output of chemically stable and biologically compatible microgels positions it as a practical tool for diverse biomedical tasks, from drug delivery to developing in vitro 3D models for therapeutic testing. By simplifying microgel production and avoiding cytotoxic processing steps, UQ-Surf offers a scalable, contamination-free alternative for regenerative medicine research. Its compatibility with living cells and high-throughput capacity make it especially promising for targeted delivery systems, gene therapies, and the future of engineered tissues. The platform’s temperature-sensitive and modular nature further supports its adaptability across a wide range of therapeutic areas.

Related Links:
University of Queensland


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.